Pediatric Targeted Therapy denied as experimental or investigational by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for pediatric targeted therapy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied This Claim — and Why You Can Appeal

BCBS's "experimental or investigational" denial for a pediatric targeted therapy is one of the most vigorously contested denial types in health insurance appeals — and one of the most frequently overturned. Insurers apply "experimental" designations based on their internal technology assessments, which can lag behind current FDA approval status, published clinical consensus, and standard-of-care practice in pediatric subspecialties. In pediatric oncology in particular, targeted agents may receive FDA approval through accelerated or breakthrough pathways, and real-world adoption by major pediatric cancer centers may precede updates to insurer coverage policies. Your appeal should directly challenge BCBS's technology assessment against current authoritative sources.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503 / ACA §2719): File a written internal appeal within the deadline on your denial notice. BCBS must have a clinical reviewer with appropriate pediatric specialty expertise review the appeal.
• External review (ACA §2719): This denial type is especially important to escalate to external review if internal appeal fails. Independent reviewers apply accepted medical standards, not insurer internal policies. File within approximately four months of the final internal denial.
• Expedited option: Pediatric serious illness almost always qualifies. Request expedited internal and external review simultaneously when the child's condition warrants urgency.

## Documentation to Gather

1. FDA approval documentation — confirm and attach the current FDA approval or clearance for the specific indication. If the drug is used off-label, gather published peer-reviewed literature and statements from the relevant pediatric specialty organization. 2. Prescriber's medical-necessity letter — the treating pediatric specialist should address BCBS's experimental designation point by point, citing current standard-of-care practice and the applicable guideline organization (e.g., COG, NCCN Pediatric, relevant subspecialty society). 3. Institutional support letter — if the prescribing institution is a recognized children's hospital or NCI-designated cancer center, a letter from the tumor board or relevant committee supporting the treatment plan significantly strengthens the appeal. 4. Diagnosis and biomarker documentation — pathology, genomic, and clinical records confirming the specific diagnosis and the basis for selecting this therapy. 5. Treatment history — prior therapies tried, with dates and outcomes from the chart.

## Criteria-Mapping Structure for Your Appeal Letter

| BCBS experimental-denial basis | Your response | |---|---| | Drug lacks sufficient clinical evidence | FDA approval status + published guideline organization support | | Not consistent with generally accepted standards | Prescriber letter + institutional support | | BCBS technology assessment finding | Date of BCBS assessment vs. current FDA/guideline status |

Note the date of BCBS's technology assessment in your appeal. If it predates a recent FDA approval or major guideline update, this discrepancy is one of the strongest grounds for external review reversal.